<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101437</url>
  </required_header>
  <id_info>
    <org_study_id>TCHIRB-I021003</org_study_id>
    <nct_id>NCT02101437</nct_id>
  </id_info>
  <brief_title>The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei City Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we
      will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the basis
      of medical criteria (clinical guidelines) routine as aspirin + clopidogrel or aspirin +
      ticagrelor, according to medical guidelines currently no other disposal alternative proposal
      (unless adverse drug tolerance or bleeding can not be administered); idea of this experiment
      for acute coronary syndrome or conventional cardiac catheterization after stenting, platelet
      miRNA expression (miR-96 , miR-200b, miR-495, miR-107) after cardiac catheterization and
      interventional treatment of clopidogrel or ticagrelor acceptance of platelet reactivity (PRU)
      correlation values (given clopidogrel or ticagrelor determined by the clinician, the patient
      follow-up experiment to track only and observation), aims to explore under different platelet
      reactivity (hyper-reactive or hypo-reactive), their differences in miRNA performance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE, PRU, miRNA</measure>
    <time_frame>12 months.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>PRU</condition>
  <condition>miRNA</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      miRNA in platelet(Platelet Rich Plasma)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        stable angina who received routine dual antiplatelet agents therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1 under DAPT (dual antiplatelet therapy) of stable angina patients for elective stent
        implantation.

        2. DAPT 24 hours after treatment PRU (platelet activity units) values. (Drug unresponsive
        patients was defined as PRU&gt; 235).

        Exclusion Criteria:

        1.Not suitable for the treatment of patients with DAPT. (Active peptic ulceration or
        bleeding) 2 patients of aspirin, clopidogrel, ticagrelor, cilostazol medication
        intolerance.

        3 contraindications for aspirin, clopidogrel, ticagrelor, cilostazol drug usage (such as
        heart failure patients not suitable for use cilostazol).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen Yueh Chung, chief doctor</last_name>
    <phone>886227093600</phone>
    <phone_ext>3741</phone_ext>
    <email>chenyuehchung.tw@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei city hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Yueh Chung, chief doctor</last_name>
      <phone>886227093600</phone>
      <phone_ext>3741</phone_ext>
      <email>chenyuehchung.tw@yahoo.com.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei City Hospital</investigator_affiliation>
    <investigator_full_name>Yueh-Chung, Chen</investigator_full_name>
    <investigator_title>chief of ICU</investigator_title>
  </responsible_party>
  <pending_results>
    <submitted>November 11, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

